Thioredoxin-1 attenuates atherosclerosis development through inhibiting NLRP3 inflammasome
1
Department of Cardiology, Yiwu Central Hospital, Yiwu, China
|
Publication type: Journal Article
Publication date: 2020-06-30
scimago Q2
wos Q3
SJR: 0.971
CiteScore: 5.8
Impact factor: 2.9
ISSN: 0969711X, 1355008X, 15590100
PubMed ID:
32607763
Endocrinology
Endocrinology, Diabetes and Metabolism
Abstract
The thioredoxin-1 has atheroprotective effects via regulating oxidative stress and inflammation. In addition, the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome also contributes to atherosclerosis development. However, whether the thioredoxin-1 suppresses atherosclerosis development by modulating the NLRP3 inflammasome remains unclear. The regulation of NLRP3 inflammasome by thioredoxin-1 was determined in vitro on macrophage cells after ox-LDL (oxidized low-density lipoprotein) stimulation. The IL-1β and caspase-1 p10 secretion were assessed by ELISA and western blot. Finally, the thioredoxin-1/NLRP3 inflammasome pathway was confirmed in apolipoprotein E-deficient mice. Thioredoxin-1 suppressed the expression of NLRP3, the secretion of IL-1β and caspase-1 p10 in vitro. And ROS stimulation activated the NLRP3 inflammasome which was inhibited by thioredoxin-1. In the mouse model of atherosclerosis, thioredoxin-1 delivered by lentivirus vector inhibited atherosclerosis development. And the atheroprotective effects of thioredoxin-1 were attenuated by ROS stimulation. Furthermore, the regulation of NLRP3 inflammasome by thioredoxin-1 was also confirmed in vivo. We demonstrated here that the thioredoxin-1 had atheroprotective functions through thioredoxin-1/NLRP3 inflammasome pathway.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
International Journal of Molecular Sciences
2 publications, 8%
|
|
|
Biomedicines
2 publications, 8%
|
|
|
European Journal of Pharmacology
2 publications, 8%
|
|
|
Antioxidants and Redox Signaling
1 publication, 4%
|
|
|
Nutrients
1 publication, 4%
|
|
|
Journal of Tissue Engineering
1 publication, 4%
|
|
|
Frontiers in Cell and Developmental Biology
1 publication, 4%
|
|
|
Frontiers in Pharmacology
1 publication, 4%
|
|
|
Cells
1 publication, 4%
|
|
|
Scientific Reports
1 publication, 4%
|
|
|
International Journal of Cardiology
1 publication, 4%
|
|
|
Cellular and Molecular Biology Letters
1 publication, 4%
|
|
|
iScience
1 publication, 4%
|
|
|
Nature
1 publication, 4%
|
|
|
Journal of Medicinal Chemistry
1 publication, 4%
|
|
|
Aging
1 publication, 4%
|
|
|
Journal of Ethnopharmacology
1 publication, 4%
|
|
|
Inflammation
1 publication, 4%
|
|
|
SLAS Discovery
1 publication, 4%
|
|
|
Archiv der Pharmazie
1 publication, 4%
|
|
|
Drug Delivery
1 publication, 4%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
|
|
|
MDPI
6 publications, 24%
|
|
|
Elsevier
6 publications, 24%
|
|
|
Springer Nature
4 publications, 16%
|
|
|
Frontiers Media S.A.
2 publications, 8%
|
|
|
Mary Ann Liebert
1 publication, 4%
|
|
|
SAGE
1 publication, 4%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 4%
|
|
|
American Chemical Society (ACS)
1 publication, 4%
|
|
|
Impact Journals
1 publication, 4%
|
|
|
Wiley
1 publication, 4%
|
|
|
Taylor & Francis
1 publication, 4%
|
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
25
Total citations:
25
Citations from 2024:
8
(32%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Wang Yu. et al. Thioredoxin-1 attenuates atherosclerosis development through inhibiting NLRP3 inflammasome // Endocrine. 2020. Vol. 70. No. 1. pp. 65-70.
GOST all authors (up to 50)
Copy
Wang Yu., Ji N., Gong X., Ni S., Xu L., Zhang H. Thioredoxin-1 attenuates atherosclerosis development through inhibiting NLRP3 inflammasome // Endocrine. 2020. Vol. 70. No. 1. pp. 65-70.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1007/s12020-020-02389-z
UR - https://doi.org/10.1007/s12020-020-02389-z
TI - Thioredoxin-1 attenuates atherosclerosis development through inhibiting NLRP3 inflammasome
T2 - Endocrine
AU - Wang, Yu
AU - Ji, Ningning
AU - Gong, Xinyang
AU - Ni, Shimao
AU - Xu, Lei
AU - Zhang, Hui
PY - 2020
DA - 2020/06/30
PB - Springer Nature
SP - 65-70
IS - 1
VL - 70
PMID - 32607763
SN - 0969-711X
SN - 1355-008X
SN - 1559-0100
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2020_Wang,
author = {Yu Wang and Ningning Ji and Xinyang Gong and Shimao Ni and Lei Xu and Hui Zhang},
title = {Thioredoxin-1 attenuates atherosclerosis development through inhibiting NLRP3 inflammasome},
journal = {Endocrine},
year = {2020},
volume = {70},
publisher = {Springer Nature},
month = {jun},
url = {https://doi.org/10.1007/s12020-020-02389-z},
number = {1},
pages = {65--70},
doi = {10.1007/s12020-020-02389-z}
}
Cite this
MLA
Copy
Wang, Yu., et al. “Thioredoxin-1 attenuates atherosclerosis development through inhibiting NLRP3 inflammasome.” Endocrine, vol. 70, no. 1, Jun. 2020, pp. 65-70. https://doi.org/10.1007/s12020-020-02389-z.